Changes/NNS
in/IN
triiodothyronine/NN
(/(
T3/NN
)/)
mononuclear/JJ
leukocyte/NN
receptor/NN
kinetics/NNS
after/IN
T3/NN
administration/NN
and/CC
multiple/JJ
cold-air/JJ
exposures/NNS
./.

Repeated/VBN
cold-air/JJ
exposures/NNS
increase/VBP
human/JJ
triiodothyronine/NN
(/(
T3/CD
)/)
plasma/NN
clearance/NN
rates/NNS
./.
=====
To/TO
study/VB
the/DT
response/NN
of/IN
the/DT
nuclear/JJ
T3/NN
receptor/NN
(/(
NT3R/NN
)/)
in/IN
this/DT
condition/NN
,/,
binding/VBG
characteristics/NNS
were/VBD
analyzed/VBN
in/IN
human/JJ
mononuclear/JJ
leukocytes/NNS
(/(
MNL/NN
)/)
./.
=====
In/IN
addition/NN
,/,
we/PRP
supplemented/VBD
one/CD
group/NN
of/IN
individuals/NNS
with/IN
a/DT
daily/RB
oral/JJ
replacement/NN
dose/NN
of/IN
T3/NN
to/TO
isolate/VB
the/DT
influence/NN
of/IN
serum/NN
thyroxine/NN
(/(
T4/NN
)/)
and/CC
thyrotropin/NN
(/(
TSH/NN
)/)
levels/NNS
on/IN
receptor/NN
kinetics/NNS
./.
=====
The/DT
subjects/NNS
were/VBD
exposed/VBN
to/TO
cold/JJ
air/NN
(/(
4/CD
degrees/NNS
C/NN
)/)
twice/d/RB
,/,
30/CD
min/exposure/NN
,/,
for/IN
a/DT
total/NN
of/IN
80/CD
exposures/NNS
./.
=====
The/DT
T3-subjects/NNS
received/VBD
placebo/NN
[/(
n/NN
=/JJ
8/CD
]/)
and/CC
the/DT
T3/NN
+/JJ
subjects/NNS
received/VBD
T3/CD
(/(
30/CD
micrograms/d/NN
)/)
[/(
n/NN
=/JJ
8/CD
]/)
in/IN
a/DT
double-blind/JJ
fashion/NN
./.
=====
Mononuclear/JJ
leukocytes/NNS
were/VBD
isolated/VBN
from/IN
peripheral/JJ
blood/NN
before/IN
the/DT
cold/JJ
exposure/NN
and/CC
drug/NN
regimen/NNS
began/VBD
,/,
and/CC
then/RB
after/IN
every/DT
20/CD
exposures/NNS
./.
=====
The/DT
dissociation/NN
constant/NN
(/(
Kd/NN
)/)
and/CC
maximum/NN
binding/NN
capacity/NN
(/(
MBC/NN
)/)
of/IN
the/DT
NT3R/NN
values/NNS
were/VBD
log/NN
transformed/VBN
to/TO
minimize/VB
between-subject/JJ
variability/NN
./.
=====
In/IN
the/DT
T3+/JJ
group/NN
,/,
serum/NN
total/VBP
thyroxine/NN
(/(
TT4/NN
)/)
,/,
free/JJ
T4/NN
(/(
FT4/NN
)/)
,/,
and/CC
TSH/NN
were/VBD
approx/RB
50/CD
%/NN
lower/JJR
than/IN
both/CC
basal/JJ
and/CC
T3-values/NNS
./.
=====
The/DT
log10Kd/NN
increased/VBD
0.304/CD
+/-/CC
0.139/CD
(/(
p/NN
</JJR
0.04/CD
)/)
and/CC
the/DT
log10MBC/NN
increased/VBD
0.49/CD
+/-/CC
0.10/CD
(/(
p/NN
</JJR
0.001/CD
)/)
in/IN
the/DT
T3+/JJ
subjects/NNS
compared/VBN
to/TO
baseline/NN
./.
=====
This/DT
change/NN
in/IN
MBC/NN
represents/VBZ
a/DT
311/CD
%/NN
increase/NN
in/IN
the/DT
MBC/NN
over/IN
baseline/NN
and/CC
a/DT
fivefold/JJ
increase/NN
over/IN
placebo-treated/JJ
subjects/NNS
./.
=====
The/DT
T3-group/NN
showed/VBD
no/DT
change/NN
in/IN
MBC/NN
over/IN
the/DT
study/NN
./.
=====
These/DT
results/NNS
describe/VBP
for/IN
the/DT
first/JJ
time/NN
the/DT
rapid/JJ
modulation/NN
of/IN
the/DT
NT3R/NN
in/IN
response/NN
to/TO
the/DT
combined/JJ
influence/NN
of/IN
cold/JJ
exposure/NN
and/CC
reduced/VBN
circulating/VBG
T4/NN
and/CC
TSH/NN
./.